Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Learn about nyse:ABBV with our data and independent analysis including share price, star rating, valuation, dividends, and financials.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

Medtronic is approaching five decades of dividend growth. AbbVie rose to the challenge when its Humira patent expired, ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ ...

A small percentage of people with ankylosing spondylitis also develop Crohn’s disease or ulcerative colitis. Learn why and what treatments may work.

Leonard Calabrese, DO, Paras Karmacharya, MD, MS, and Adam Kilian, MD, explore how the older average age of patients with GCA ...

(Reuters) -The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie will also acquire Capstan’s CellSeeker tLNP platform technology, which is designed to deliver RNA payloads, such as ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...